Events in 2023
CONGRESS 2023 - Development & Introduction of ISO 15189:2022
25/09/2023
ISO15189:2022 has undergone a major revision and was release in December 2022. David was one of the core drafting team responsible for the latest version and will discuss how the document was developed and agreed by the international community, why the changes were made and the purpose of the new standard.
Areas covered in this lecture will include the change in the format of the standard, why Point of Care testing is now part of the main assessment, if applicable and the increased empathies on risk and patient welfare.ISO15189 was revised and released in December.
Areas covered in this lecture will include the change in the format of the standard, why Point of Care testing is now part of the main assessment, if applicable and the increased empathies on risk and patient welfare.ISO15189 was revised and released in December.
CONGRESS 2023 - Uropathology
25/09/2023
A brief overview of two interesting case studies in uropathology covering the normal histology of the kidney and prostate, the common tumour types/pathologies and the potential challenges or differential diagnoses that may need to be considered.
CONGRESS 2023 - Making Science Sustainable – Laboratory Efficiency Assessment Framework (LEAF) and Clinical Laboratories
26/09/2023
Nations, institutions, and now the NHS have made net-zero commitments, but how will this affect scientific operations, and what would net-zero science look like? Laboratories are recognising their energy intensive nature, and assessing their immense consumption of consumables. More green lab efforts are growing around the world, though more standards are needed.
This talk will include:
An introduction to sustainable and green labs
A look at what net-zero laboratories might resemble in the future
An introduction to Sustainability standards, and what programmes are developing regarding the sustainability of clinical, research, and all kinds of labs
Questions!
This talk will include:
An introduction to sustainable and green labs
A look at what net-zero laboratories might resemble in the future
An introduction to Sustainability standards, and what programmes are developing regarding the sustainability of clinical, research, and all kinds of labs
Questions!
CONGRESS 2023 - Clinical and economic evaluation of the clinical utility of UCH-L1 and GFAP in mild TBI
26/09/2023
There are 1.4 million UK ED attendances for head injury every year. Up to 2/3 of these are in adult patients. The severity of head injury associated traumatic brain injury (TBI) is assessed clinically using the Glasgow Coma Score (GCS). The majority of fatal outcomes occur in moderate TBI (GCS 9-12) or severe TBI (GCS=8), which account for only 5% of attenders.
The presence of severe TBI is usually clinically clear cut and prompt evaluation using computed tomography (CT) imaging of the brain is performed, followed by hospital admission with further detailed evaluation. This is also often the case where moderate TBI is suspected. There is clearly a need to identify patients that account for the remaining 95% of attenders, with minor or mild head injuries, who will go on to have serious intracranial lesions.
In patients with GCS 13-15, however, only 1/10 demonstrate evidence of pathology on CT scan.
The measurement of serum biomarkers of brain injury has been proposed as a method to accurately differentiate those patients with GCS 13-15 who are likely to have underlying pathology from those with GCS 13-15 with no underlying pathology.
Among the most studied biomarkers are Ubiquitin C-terminal hydroxylase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP). UCH-L1 GFAP have been shown to correlate with TBI severity and clinical outcomes. Current evidence indicates that both serum GFAP and UCH-L1 are detectable in serum in less than 1 hour following a mTBI. GFAP and UCH-L1 levels are significantly elevated in patients with TBI with intracranial lesions on computed tomography (CT) and, in patients with mTBI, can distinguish between those with a normal and an abnormal CT scan of the brain.
Patients with mild TBI are at low risk of clinically significant brain injury in the absence of raised serum GFAP and UCH-L1 and other associated risk factors. They do not require a CT head scan and may be safely discharged providing there is a safe support system of care. It is anticipated that this could reduce head CT in these patients by 40%.
Methodology and preliminary results form an ongoing clinical and economic evaluation of the FDA approved serum GFAP and UCH-L1 on the Abbott Alinity platform in patients with mTBI will be presented.
The presence of severe TBI is usually clinically clear cut and prompt evaluation using computed tomography (CT) imaging of the brain is performed, followed by hospital admission with further detailed evaluation. This is also often the case where moderate TBI is suspected. There is clearly a need to identify patients that account for the remaining 95% of attenders, with minor or mild head injuries, who will go on to have serious intracranial lesions.
In patients with GCS 13-15, however, only 1/10 demonstrate evidence of pathology on CT scan.
The measurement of serum biomarkers of brain injury has been proposed as a method to accurately differentiate those patients with GCS 13-15 who are likely to have underlying pathology from those with GCS 13-15 with no underlying pathology.
Among the most studied biomarkers are Ubiquitin C-terminal hydroxylase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP). UCH-L1 GFAP have been shown to correlate with TBI severity and clinical outcomes. Current evidence indicates that both serum GFAP and UCH-L1 are detectable in serum in less than 1 hour following a mTBI. GFAP and UCH-L1 levels are significantly elevated in patients with TBI with intracranial lesions on computed tomography (CT) and, in patients with mTBI, can distinguish between those with a normal and an abnormal CT scan of the brain.
Patients with mild TBI are at low risk of clinically significant brain injury in the absence of raised serum GFAP and UCH-L1 and other associated risk factors. They do not require a CT head scan and may be safely discharged providing there is a safe support system of care. It is anticipated that this could reduce head CT in these patients by 40%.
Methodology and preliminary results form an ongoing clinical and economic evaluation of the FDA approved serum GFAP and UCH-L1 on the Abbott Alinity platform in patients with mTBI will be presented.
CONGRESS 2023 - Your career in Clinical Biochemistry: IBMS qualifications and the role of the Advisory Panel
26/09/2023
Your career in Clinical Biochemistry: IBMS qualifications and the role of the Advisory Panel
CONGRESS 2023 - Overcoming challenges to passing cervical cytology exams
26/09/2023
Overcoming challenges to passing cervical cytology exams
Page 9 of 35